VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF
) ( BioVaxys or Company ) announced today that it has signed a Term Sheet ( Term Sheet ) with BioElpida S.A.S. ( BioElpida ) of Lyon, France, to collaborate on the build-out for the clinical-grade manufacturing process and aseptic packaging for BXV-0918A, BioVaxys vaccine for Stage III/Stage IV ovarian cancer. Completion of the GMP-grade bioproduction process development is planned for later this year, with the EU Phase I/II clinical trial slated for early 2022, pending European Medicines Agency ( EMEA ) approval.
BioElpida is a biotechnology contract development and manufacturing company ( CDMO ) which applies single-use bioprocessing for development and manufacturing of biological and cell-based products. BioElpida s expertise extends from R&D to pharmaceutical manufacturing and release of clinical batches, and intermediate steps such as process development, feasibility
Financial News Media | Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients financialnewsmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialnewsmedia.com Daily Mail and Mail on Sunday newspapers.